DataMeds AI launches Galectovid for cold and flu season
Analysis based on 10 articles · First reported Aug 27, 2026 · Last updated Aug 27, 2026
The launch may boost DataMeds AI's revenue and market presence in the OTC cold and flu segment, potentially positively impacting its stock. Tollo Health and Corexa Pharmacy may see increased sales, while Amazon (company) could benefit from distribution.
DataMeds AI, Inc. (NASDAQ:MEDS) announced the U.S. direct-to-consumer launch of Galectovid, a medical food for the dietary management of galectin-1 and galectin-3 associated viral infections, for the 2026 Cold & Flu Season. The product is available over-the-counter at Tollo Health's online store and at DataMeds AI's wholly-owned pharmacy Corexa Pharmacy's online store, with plans to expand to Health Lives Here pharmacies and Amazon (company). Galectovid is categorized as a medical food under the Orphan Drug Act and its ingredients are on the FDA's Generally Recognized as Safe list. The company is offering a 50% discount through its #Back2School50% campaign. Interim co-CEO Gerald Commissiong expressed confidence in the product and noted expansion of research activities through physician relationships.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard